AbbVie (ABBV)
210.60
+1.10 (0.53%)
NYSE · Last Trade: Aug 22nd, 5:10 PM EDT
Detailed Quote
Previous Close | 209.50 |
---|---|
Open | 210.84 |
Bid | 209.81 |
Ask | 210.28 |
Day's Range | 207.12 - 211.47 |
52 Week Range | 163.81 - 218.66 |
Volume | 4,818,560 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 6.560 (3.11%) |
1 Month Average Volume | 4,959,774 |
Chart
About AbbVie (ABBV)
AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More
News & Press Releases
Daily stock price moves often dominate headlines, but shifts in fundamental ranking scores can reveal a deeper story. This week, Benzinga's proprietary Growth data highlighted major swings among household names.
Via Benzinga · August 22, 2025
Sit back and let the income roll in with this great exchange-traded fund.
Via The Motley Fool · August 22, 2025
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Via StockStory · August 22, 2025
The annual Jackson Hole Economic Policy Symposium, a highly anticipated gathering of global central bankers, finance ministers, and leading economists, is currently underway in Wyoming. This year's symposium is particularly significant as Federal Reserve Chair Jerome Powell's final keynote address before his term concludes in May 2026 is expected to
Via MarketMinute · August 21, 2025
Global financial markets are on tenterhooks, fixated on the highly anticipated speech by Federal Reserve Chair Jerome Powell at the annual Jackson Hole Economic Symposium. Investors are keenly awaiting any signals regarding the future trajectory of U.S. monetary policy, with a significant portion of the market pricing in a
Via MarketMinute · August 21, 2025
Via Benzinga · August 21, 2025
AbbVie's Rinvoq Phase 3 trial showed strong efficacy in severe alopecia areata, with many patients achieving significant scalp hair regrowth by week 24.
Via Benzinga · August 21, 2025
AbbVie’s Investigational Drug For Alopecia Yields Positive Outcomes In Late-Stage Studystocktwits.com
Via Stocktwits · August 21, 2025
These high-yield dividend stocks are built to last.
Via The Motley Fool · August 21, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.
Via StockStory · August 19, 2025
The financial world is abuzz with anticipation as the annual Jackson Hole Economic Symposium draws near, an exclusive gathering hosted by the Federal Reserve Bank of Kansas City in the serene mountains of Wyoming. This highly influential event, bringing together central bank leaders, economists, and financial market participants from across
Via MarketMinute · August 19, 2025
Investor sentiment is overwhelmingly pointing towards a significant shift in the Federal Reserve's monetary policy, with a near-certainty of a 25-basis-point interest rate cut anticipated at its September meeting. This widespread expectation, currently hovering around a 92% probability, is sending ripples through financial markets, influencing everything from stock valuations to
Via MarketMinute · August 19, 2025
You'd be sitting pretty right now.
Via The Motley Fool · August 18, 2025
Marjorie Taylor Greene may have another winning stock trade with a new filing showing a purchase of UnitedHealth stock.
Via Benzinga · August 15, 2025
Via Benzinga · August 15, 2025
These stocks offer great dividends and more.
Via The Motley Fool · August 15, 2025
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via StockStory · August 15, 2025
Optimism has surged through financial markets as recent economic data, particularly the July Consumer Price Index (CPI), has significantly bolstered expectations for a 25-basis-point interest rate cut by the Federal Reserve in September. This shift in sentiment reflects a growing belief that the central bank may pivot towards supporting economic
Via MarketMinute · August 14, 2025
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · August 14, 2025
A surprisingly subdued July Consumer Price Index (CPI) report has sent ripples of optimism across global financial markets, igniting a worldwide rally and significantly recalibrating expectations for future interest rate movements. With a modest 0.2% monthly increase and a 2.7% year-over-year rise, the inflation data was largely perceived
Via MarketMinute · August 13, 2025
Pharmaceutical company AbbVie (NYSE:ABBV) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above analysts’ consensus estimates.
Via StockStory · August 13, 2025
These tried-and-true businesses are performing well against a volatile backdrop.
Via The Motley Fool · August 10, 2025
All four pay safe, reliable, and growing dividends.
Via The Motley Fool · August 9, 2025
These stocks check off all the boxes for investors no longer receiving a paycheck.
Via The Motley Fool · August 9, 2025
This ultra-low-cost ETF is an excellent way to invest in large-cap value stocks, many of which pay dividends.
Via The Motley Fool · August 9, 2025